FDA approves first dermal filler to treat acne scarring

By Natalie Grover (Reuters) – The U.S. Food and Drug Administration approved the first dermal filler to treat scarring caused by acne, the most common skin disorder in the United States afflicting 40-50 million people. Bellafill, developed by privately held Suneva Medical Inc, is made primarily of bovine collagen. When injected, it lifts and smoothens pitted scars to the level of the surrounding skin. It is designed to treat moderate to severe acne scars on the cheeks of patients over the age of 21, Suneva said on Tuesday. A cure for acne has long eluded drug developers. …
Go to Source

DASH named best overall diet for fifth year: report

By Patricia Reaney NEW YORK (Reuters) – The DASH diet, rich in vegetables, whole grains and low-fat dairy, has been named the best overall diet for the fifth consecutive year, outpacing Weight Watchers and the Mediterranean diet, U.S. News & World Report said on Tuesday. DASH, which was developed to lower blood pressure without medication, was also chosen by a panel of health experts as the top diabetes diet and the best plan for healthy eating. Weight Watchers retained the No. …
Go to Source

WHO says reports of suspected Ebola cases in Iraq are untrue

LONDON (Reuters) – No suspected cases of Ebola have been found in Iraq, despite reports to the contrary in Iraqi media in the past week, the World Health Organization (WHO) said on Tuesday. Describing reports of suspect cases of the deadly viral infection in Mosul as “rumor”, the Geneva-based United Nations health agency said it and the Iraqi health ministry had conducted a full investigation. “All sources contacted have negated the existence of any suspected cases of Ebola,” the WHO said in a statement. …
Go to Source

Exercise Linked to Parkinson’s Prevention

Research evidence continues to mount that physical exercise may help lower a person’s risk of developing Parkinson’s disease. In a new study that followed 43,368 men and women in Sweden for about 13 years, moderate daily exercise was found to be associated with a lower risk of Parkinson’s. Parkinson’s belongs to a group of conditions called […]
Go to Source

Cytrx cancer drug shows promise in trial, shares rise

(Reuters) – Cytrx Corp said interim data showed its experimental cancer drug was effective in a mid-stage trial on patients with a deadly form of brain cancer, sending its shares up 33 percent before the bell. The drug, aldoxorubicin, was tested in patients with glioblastoma multiforme (GBM) whose tumors had progressed post surgery as well as radiation and was successful in preventing further progression and shrank tumors in several patients. GBM is the most deadly form of brain cancer and affects more than 12,000 people in the United States annually, the company said. …
Go to Source

1 333 334 335 336 337 345